Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Advantech Europe
KOREA E & EX

Robot-Assisted Technique Improves Small Kidney Tumor Removal

By HospiMedica International staff writers
Posted on 24 Jul 2014
A new study demonstrates that retroperitoneoscopic partial nephrectomy (RARPN) is preferable for excising posterior kidney tumors less accessible through traditional minimally invasive surgery (MIS) approaches.

Researchers at the University of California, Los Angeles (UCLA; USA), the Swedish Medical Center (Seattle, WA, USA), and the University of Michigan (Ann Arbor, USA) conducted a retrospective multicenter study of 227 consecutive RARPNs performed between 2006 to 2013. The researchers assessed positive margins and cancer recurrence, examining factors associated with complications, estimated blood loss (EBL), warm ischemia time (WIT), operative time (OT), and length of stay (LOS). Median patient age was 60 and median body mass index (BMI) was 28.2 kg/m2.

The results showed that 28 subjects (12.3%) experienced complications, three (1.3%) had urine leaks, and three (1.3%) had pseudoaneurysms that required reintervention. Intersurgeon variation was associated with complications and WIT, with higher surgeon volume associated with shorter WIT. Higher BMI was associated with longer OT, and longer OT was associated with longer LOS. There was also a trend for intersurgeon variation in OT. The study was published online on May 21, 2014, in European Urology.

“RARPN has acceptable morbidity and oncologic outcomes, despite intersurgeon variation in WIT and complications. These differences in warm ischemia time may be attributable to slight variations in surgical technique,” said lead author Jim Hu, MD, of the UCLA Jonsson Comprehensive Cancer Center. “But we showed center-specific variations in the RARPN approach and we present a video on surgical technique to highlight our approach.”

Small renal masses are a heterogeneous group of tumors, and only 20% are aggressive renal cell carcinoma. In general, nephron-sparing treatments are preferred to avoid chronic kidney disease (CKD), which often occurs after radical nephrectomy. RARPN, thermal ablation, and active surveillance are all valid treatment strategies in select patients who are not optimal surgical candidates or who have limited life expectancy.

WIT refers to the amount of time the renal artery, the main blood supply to the kidney, is blocked off during surgery. Longer WITs are associated with increased complications, such as acute kidney failure and long-term CKD.

Related Links:

University of California, Los Angeles
Swedish Medical Center
University of Michigan



Channels

Critical Care

view channel
Image: Repellent surface technology prevents biofilm formation (Photo courtesy of Joanna Aizenberg/ Harvard).

Slippery Surface Technology Repels Bacterial Biofilm

Novel lubricant-infused slippery polymers could serve as a long lasting, self-replenishing solution to repel deadly bacterial build-up in medical devices. Researchers at Harvard University (Cambridge,... Read more

Women's Health

view channel

Nitrous Oxide for Labor Makes US Comeback

Long used for its anxiolytic properties during labor in European countries and Canada, nitrous oxide (N2O) use is resurging in the United States. While in countries such as Norway, New Zealand, Sweden, Australia, and England, usage rates of inhalational N2O during parturition reach 70%, it has only recently become an... Read more

Health IT

view channel
Image: ResolutionMD across multiple devices (Photo courtesy of Calgary Scientific).

Healthcare Communication Platform Offers Seamless Image Access

Novel diagnostic medical imaging software offers better access to health information, supports increased teamwork, and enhances communication among practitioners and patients. ResolutionMD enables doctors... Read more

Business

view channel

Pfizer to Buy Hospira to Bolster Hospital Products

Pfizer (New York, NY, USA) has entered into a definitive merger agreement with Hospira (Lake Forest, IL, USA), in a move designed to significantly enhance their global established pharmaceutical (GEP) business, for a total enterprise value of approximately USD 17 billion. The strategic complementary combination will... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.